Pages

▼
Showing posts with label Pfizer. Show all posts
Showing posts with label Pfizer. Show all posts
February 27, 2016

A new article, a new clinical trial

›
Last week Reuters' Bill Berkrot wrote an article on Provectus, its drug PV-10 and the drug's active pharmaceutical ingredient Rose B...
January 14, 2016

"Going to be a leading player in 2nd wave of combos."

›
Blog post title attribution: From a tweet by @lisamjarvis below: Click to enlarge. Image source Provectus issued a press release yeste...
August 9, 2015

Potential Catalysts & "Catalysts"

›
Caveat: I have been hilariously off-base in the past. See, for example, my August 31, 2014 blog post  Potential Catalysts . Updated ...
January 27, 2015

"Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office"

›
Image source Provectus issued press release Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Pate...
January 18, 2015

Dr. Weber

›
An interview of Moffitt Cancer Center's Dr. Jeffrey Weber, M.D., Ph.D. by OncLive's Andrew Roth , Expert Discusses Integration of ...
December 21, 2014

Let Me Tell You A Story About Pfizer

›
Provectus  issued a press release  and  filed an associated 8-K  this past week regarding the addition of a third Pfizer executive to its st...
November 18, 2014

Provectus notebook

›
Pilon-Thomas & Moffitt Cancer Center. Frequent medical writer of PV-10 Janet Fricker has an article out in Medical News Today today  ...
October 14, 2014

The Immune Checkpoint Inhibitor Global 4 (or 5)

›
In 2013 Citi equity research analyst Andrew Baum projected cancer immunotherapies "...will generate sales of up to $35 billion (a year)...